Pain Summit

HEALING CHRONIC PAIN SUMMIT "There is, most likely, at the current stage of our knowledge, a programming phase early on that makes the brain more vulnerable later to develop a chronic pain syndrome." https://youtu.be/sqfZQw0UOvQ Join thousands who are registering to watch this online summit with 47 leading experts. In this summit, we acknowledge and recognize that everybody has a unique story around their pain and we empathize with what you are going through. We are also shedding light on different ways of looking at chronic pain. We want to give you some new keys to unlock the doorway to reclaiming your quality of life. Each story is unique, and various kinds of chronic pain can be different manifestations of similar deep rooted imbalances in the body, mind, and spirit. Here is a preview of my presentation: https://youtu.be/qfGYHM0cCTY Click here to access the Healing Chronic Pain Summit The Pain Summit Facebook page is here.

Fascinating study reporting results obtained from nearly 12,000 people around the world as part of the American Gut Project

'Largest' microbiome study weighs in on our gut health Fascinating study reporting results obtained from nearly 12,000 people around the world as part of the American Gut Project.  Major findings of this landmark study are the fact that it is the diversity of plant based foods that a person consumes (and not just the fact that somebody identifies as vegan or vegetarian) that influences gut microbial diversity and relative abundances, and that there is an association of mental disorders with gut microbial function, with gut microbial characteristics being more similar amongst several psychiatric diseases than compared to healthy individuals.  Even though the findings are solely based on associations, and do not allow to make statements about causality, they represent the most comprehensive analysis of gut microbial data published to date.  

Important implications for development of future therapeutic strategies using engraftment of microbial species into our gut microbiome.

An exclusive metabolic niche enables strain engraftment in the gut microbiota Elizabeth Stanley Shepherd, William C. DeLoache , Kali M. Pruss , Weston R. Whitaker & Justin L. Sonnenburg   After programming of the general compositional architecture of the gut microbiota in early life, the established microbial ecosystem remains fairly stable and resilient to perturbations throughout life. Such perturbations include infections, colonic cleansing, diet or antibiotic intake.  While this is stability and resilience is generally of great benefit for the host, it becomes a challenge when we try to modify an compromised microbiome by the intake of probiotics or fecal microbial transplantation.  Before we can move on to modulate a maladaptive or disease related gut microbial composition by such interventions, there is a need for basic insight into the factors that influence whether and under what circumstances new strains of bacteria can integrate into a pre-existing, complex microbiota. This latest study from the Sonnenburg lab demonstrates in mice that the combined administration of a specific sugar molecule called porphyry and a microbial strain that is not part of the normal gut microbiota but which contains the genes for the exclusively utilization of this sugar molecule results in the engraftment of the new microbe into the existing gut microbial ecosystem. As stated by the authors: "Privileged nutrient access enables reliable engraftment of the exogenous strain at predictable abundances in mice harbouring diverse communities of gut microbes. These findings have important implications for the development of future therapeutic strategies using the engraftment of lacking or novel microbial species into our gut microbiome.  Such strategies may become important of the treatment of such various disorders as autism spectrum disorders, inflammatory bowel disorders and obesity.    

IBS Patients Obtain Robust, Enduring Relief from Home-Based Treatment Program–And Physicians Agree

"This study clearly established the clinical value of a #MindBased intervention for Irritable Bowel Syndrome (IBS)... showing that this should be offered to patients not as a last resort but as a safe and effective first or second-line therapy." - Dr. Emeran Mayer Landmark, NIH-funded multisite study finds IBS patients who learned to control severe GI symptoms at home saw as much benefit as those treated with multiple clinic visits... BUFFALO, N.Y. — In the largest federally funded clinical non-drug trial for irritable bowel syndrome (IBS), patients with the most severe and persistent symptoms achieved robust and sustained relief by learning to control symptoms with minimal clinician contact. Led by University at Buffalo researchers in collaboration with colleagues at New York University and Northwestern University, the study is published in Gastroenterology. The research is a product of 20 years of funding from the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health, and one of the largest, behavioral medicine trials not including a drug arm. It reflects a longtime partnership between researchers at UB and NYU, who pooled their respective expertise and talents to develop and test a novel treatment strategy. Of 436 patients recruited at UB and Northwestern, 61 percent reported symptom improvement two weeks after home-based behavioral treatment ended compared to 55 percent in clinic-based treatment and 43 percent who received patient education. The treatment benefit also persisted for as long as six months after treatment ended. “This is a novel, game-changing treatment approach for a public health problem that has real personal and economic costs, and for which there are few medical treatments for the full range of symptoms,” said Jeffrey Lackner, PsyD, lead author, professor in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences at UB and director of its Behavioral Medicine Clinic. He is affiliated with UB’s Clinical and Translational Science Institute. Women are disproportionately affected IBS is a persistent and difficult-to-treat condition that is one of the most common diseases that gastroenterologists and primary care physicians treat. It’s characterized by chronic abdominal pain, diarrhea and/or constipation. Medical and dietary treatment have a disappointing track record of relief for many patients. Afflicting between 10 and 15 percent of adults worldwide, most of whom are female, the condition creates a public health burden that causes pain, isolation and frustration, all of which impair quality of life. Beyond…